Switch theme
Sign up to access all valuation multiples
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
2018
78
LTM Revenue $0.1M
Last FY EBITDA -$88.2M
-$113M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Acrivon Therapeutics has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Acrivon Therapeutics achieved revenue of n/a and an EBITDA of -$88.2M.
Acrivon Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Acrivon Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | -$0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | -97% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$88.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$90.9M | XXX | -$89.2M | XXX | XXX | XXX |
| EBIT Margin | -150967% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$83.9M | XXX | -$80.6M | XXX | XXX | XXX |
| Net Margin | -139335% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Acrivon Therapeutics's stock price is $1.
Acrivon Therapeutics has current market cap of $33.4M, and EV of -$113M.
See Acrivon Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$113M | $33.4M | XXX | XXX | XXX | XXX | $-2.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Acrivon Therapeutics has market cap of $33.4M and EV of -$113M.
Acrivon Therapeutics's trades at n/a EV/Revenue multiple, and 1.3x EV/EBITDA.
Equity research analysts estimate Acrivon Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Acrivon Therapeutics has a P/E ratio of -0.4x.
See valuation multiples for Acrivon Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $33.4M | XXX | $33.4M | XXX | XXX | XXX |
| EV (current) | -$113M | XXX | -$113M | XXX | XXX | XXX |
| EV/Revenue | -1872.8x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBIT | 1.2x | XXX | 1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1939.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAcrivon Therapeutics's last 12 month revenue growth is 1176%
Acrivon Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
Acrivon Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Acrivon Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Acrivon Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1176% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acrivon Therapeutics acquired XXX companies to date.
Last acquisition by Acrivon Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Acrivon Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Acrivon Therapeutics founded? | Acrivon Therapeutics was founded in 2018. |
| Where is Acrivon Therapeutics headquartered? | Acrivon Therapeutics is headquartered in United States of America. |
| How many employees does Acrivon Therapeutics have? | As of today, Acrivon Therapeutics has 78 employees. |
| Who is the CEO of Acrivon Therapeutics? | Acrivon Therapeutics's CEO is Mr. Peter Blume-Jensen, M.D.,PhD. |
| Is Acrivon Therapeutics publicy listed? | Yes, Acrivon Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Acrivon Therapeutics? | Acrivon Therapeutics trades under ACRV ticker. |
| When did Acrivon Therapeutics go public? | Acrivon Therapeutics went public in 2022. |
| Who are competitors of Acrivon Therapeutics? | Similar companies to Acrivon Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Acrivon Therapeutics? | Acrivon Therapeutics's current market cap is $33.4M |
| What is the current revenue of Acrivon Therapeutics? | Acrivon Therapeutics's last 12 months revenue is $0.1M. |
| What is the current revenue growth of Acrivon Therapeutics? | Acrivon Therapeutics revenue growth (NTM/LTM) is 1176%. |
| What is the current EV/Revenue multiple of Acrivon Therapeutics? | Current revenue multiple of Acrivon Therapeutics is -1872.8x. |
| Is Acrivon Therapeutics profitable? | Yes, Acrivon Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
